Supernus Pharmaceuticals to buy VC-backed Biscayne Neurotherapeutics

Supernus Pharmaceuticals Inc has agreed to acquire Miami-based Biscayne Neurotherapeutics, a developer of treatment for epilepsy, for up to $183 million. Biscayne's backers include Quark Venture, GF Securities and Mesa Verde Venture Partners.

DealsNorth AmericaUSHealthcareBriefs